{
    "code": 0,
    "data": [
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Submission of copies of newspaper advertisement of the financial results of the Company for the third quarter and nine months period ended December 31 2025 as published in Business Standard and Nava Telangana on February 11 2026.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6573e2a2-19d2-4aea-96dd-30e40baf2127.pdf",
            "news_date": "2026-02-11 11:51:15"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Completion Of US FDA Inspection At Unit-VII Of Aurobindo Pharma Limited Jedcherla",
            "news_body": "Intimation of completion of US FDA inspection at Unit VII of the Company at Jedcherla.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b775c58c-7e85-45e4-8686-ff38ee461343.pdf",
            "news_date": "2026-02-10 22:04:17"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Submission of the revised presentation that would be used in the Investors/ Analysits call on Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31 2025 to be held today i.e February 10 2026 at 8.30 a.m.",
            "news_id": "07076a3c-9a0b-49d4-bb49-ae7157e3b293",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=04527598-c3a8-4c8c-a952-b486638c9178.pdf",
            "news_date": "2026-02-10 06:58:15",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Submission of the revised presentation that would be used in the Investors/ Analysits call on Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31 2025 to be held today i.e February 10 2026 at 8.30 a.m.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=04527598-c3a8-4c8c-a952-b486638c9178.pdf",
            "news_date": "2026-02-10 06:58:15"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Restructuring",
            "caption": "Announcement under Regulation 30 (LODR)-Restructuring",
            "news_body": "Intimation of scheme of amalgamation of two wholly owned subsidiaries of the Company.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=16f38e42-4aaa-4bb2-ab01-61ee333e197b.pdf",
            "news_date": "2026-02-09 20:05:40"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Acquisition",
            "caption": "Announcement under Regulation 30 (LODR)-Acquisition",
            "news_body": "Intimation of acquisition of stake in Garuda Renewables Private Limited.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8bc07a68-04b2-466c-9991-dc130e8c28f3.pdf",
            "news_date": "2026-02-09 20:00:56"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Directorate",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Directorate",
            "news_body": "Intimation of change in directors.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0178b724-ed65-4439-a576-6707d33f00a1.pdf",
            "news_date": "2026-02-09 19:56:26"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Submission of investor presentation on unaudited financial results for the quarter and nine months period ended December 31 2025.",
            "news_id": "d8514771-f823-43a9-bbbb-f4b36d014f2c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ca5c35e2-908b-4fbc-94d1-07553c6f2594.pdf",
            "news_date": "2026-02-09 19:50:38",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Submission of investor presentation on unaudited financial results for the quarter and nine months period ended December 31 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ca5c35e2-908b-4fbc-94d1-07553c6f2594.pdf",
            "news_date": "2026-02-09 19:50:38"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Submission of Press Release on Unaudited Financial Results for the quarter and nine months period ended December 31 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1f98fed9-360b-480d-9050-275b5c5b24c7.pdf",
            "news_date": "2026-02-09 19:48:19"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter  And Nine Months Ended December 31 2025",
            "news_body": "Submission of unaudited financial results for the quarter and nine months period ended December 31 2025.",
            "news_id": "eb37caf6-5318-43f0-ab43-1d55c4c38a30",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d3d9a63a-1119-42ea-a844-2814388d6a99.pdf",
            "news_date": "2026-02-09 19:36:56",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter  And Nine Months Ended December 31 2025",
            "news_body": "Submission of unaudited financial results for the quarter and nine months period ended December 31 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d3d9a63a-1119-42ea-a844-2814388d6a99.pdf",
            "news_date": "2026-02-09 19:36:56"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
            "news_body": "Outcome of Board meeting held on February 9 2026",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ad2fd86e-2df4-45a7-8912-2a9549cafcba.pdf",
            "news_date": "2026-02-09 19:21:20"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Completion Of US FDA Inspection At Unit III Of Eugia Pharma Specialities Ltd. A Wholly Owned Subsidiary Of The Company",
            "news_body": "Intimation of completion of US FDA inspection at Unit III of Eugia Pharma Specialities Limited a wholly owned subsidiary of the Company.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c06355e1-d734-4493-a773-513dcf8336b3.pdf",
            "news_date": "2026-02-06 18:22:50"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of participation in Axis Capitals India Investor Conference to be held on February 12 2026.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3a6010ca-ce8f-4f0c-99c0-022078bd7731.pdf",
            "news_date": "2026-02-05 12:02:16"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of participation in Nuvamas India Investor Conference to be held on February 11 2026.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5b1b5606-ad1b-4659-bb2e-4c5b8f47efae.pdf",
            "news_date": "2026-02-05 12:00:05"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of date of earning call on the Unaudited Financial Results for the third quarter and nine months period ended December 31 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=12d29971-ddbd-4d47-bd11-3b24b6d4317e.pdf",
            "news_date": "2026-02-02 10:27:48"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Clarification On Significant Volume Movement In CompanyS Shares",
            "news_body": "Submission of clarification on significant volume movement in Companys shares.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8edd237c-78a6-4aac-9e1f-23fd24bad405.pdf",
            "news_date": "2026-02-02 10:07:06"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General",
            "descriptor": "Clarification",
            "caption": "Clarification sought from Aurobindo Pharma Ltd",
            "news_body": "The Exchange has sought clarification from Aurobindo Pharma Ltd on February 01 2026 with reference to Movement in Volume.<BR><BR>The reply is awaited.",
            "file_url": "",
            "news_date": "2026-02-01 12:37:28"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Clarification On Significant Volume Movement In CompanyS Shares",
            "news_body": "Submission of clarification on significant volume movement in Companys shares sought vide letter No.NSE/CM/Surveilance/16398 dated January 30 2026.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=82c8a771-e279-4d80-99b4-10cb10b74f2b.pdf",
            "news_date": "2026-01-31 11:15:59"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Intimation Of Board Meeting Date",
            "news_body": "Aurobindo Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2026 inter alia to consider and approve This is to inform that a Meeting of the Board of Directors of the Company will be held on Monday February 9 2026 to consider and approve inter alia the Standalone & Consolidated Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f5370700-2f08-49d4-aae5-cd5fb0370d82.pdf",
            "news_date": "2026-01-30 16:43:04"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Acquisition",
            "caption": "Announcement under Regulation 30 (LODR)-Acquisition",
            "news_body": "Intimation of incorporation of new step-down Subsidiary in Philippines.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=29ec8d68-bfea-4873-b0c5-4d9b7045e53c.pdf",
            "news_date": "2026-01-23 17:09:21"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Curateq Biologics Receives NOC From Health Canada For Its Biosimilar Dyrupeg",
            "news_body": "Intimation of receipt of Notice of Compliance from Health Canada by Curateq Biologics Private Limited a wholly owned subsidiary of the Company for its biosimilar Dyrupeg.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b6419f51-46fb-4a24-9fe2-8e1842081ecd.pdf",
            "news_date": "2026-01-09 15:19:45"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of plant visit by investors.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b4022f85-d79c-4902-9fa0-e5c4f559234f.pdf",
            "news_date": "2026-01-08 17:16:21"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "Submission of certificate under Regulation 74(5) of SEBI (DP Regulations 2018 for the quarter ended 31.12.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7327a7ce-9807-464e-95ec-f0b44eb995fd.pdf",
            "news_date": "2026-01-05 12:20:55"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Acquisition",
            "caption": "Announcement under Regulation 30 (LODR)-Acquisition",
            "news_body": "Intimation of the   acquisition of the branded non-oncology prescription formulations business  of Khandelwal Laboratories Private Limited by Auro Pharma Limited a wholly owned subsidiary of the Company.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0e96b535-a0c4-410c-8a2b-8109d142582e.pdf",
            "news_date": "2026-01-01 18:05:27"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Acquisition",
            "caption": "Announcement under Regulation 30 (LODR)-Updates on Acquisition",
            "news_body": "Update on acquisition of 26% Stake in Swarnaakshu Solar Power Private Limited.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=69bce735-4958-4f33-9552-c9b65394bbf6.pdf",
            "news_date": "2025-12-30 11:15:45"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Curateq Biologics Private Limited A Wholly Owned Subsidiary Of The Company Has Mutually Agreed To Terminate Its Agreement With Biofactura Inc USA",
            "news_body": "This is to inform that Curateq Biologics Private Limited a wholly owned subsidiary of the Company has mutually agreed to terminate its agreement with BioFactura Inc. USA.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4d320b09-7ec2-4772-8b78-8fd756bde249.pdf",
            "news_date": "2025-12-27 11:54:10"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "Intimation of closure of trading window",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f1d3eb1d-1b51-4f1d-97a7-51e86c4b8e7c.pdf",
            "news_date": "2025-12-24 11:59:03"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Acquisition",
            "caption": "Announcement under Regulation 30 (LODR)-Acquisition",
            "news_body": "Intimation of acquisition of additional 20% stake in Luoxin Aurovitas (Chengudu) Co.Ltd China a Joint Venture company.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4e8ccd9c-8b6f-45b9-b34c-eab66713f216.pdf",
            "news_date": "2025-12-23 13:28:50"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Completion Of US FDA Inspection At Unit-IV Of APL Healthcare Limited A Wholly Owned Subsidiary Of The Company",
            "news_body": "Intimation of completion of US FDA inspection at Unit-IV of APL Healthcare Limited Limited a wholly owned subsidiary of the Company.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6eafb27d-307a-4cad-b6b3-5ac8eb7fdc66.pdf",
            "news_date": "2025-12-18 10:06:13"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of investor meet.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1dab478a-4507-4c62-b03b-edd0be4f7a18.pdf",
            "news_date": "2025-12-15 14:33:17"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Completion Of US FDA Inspection At Unit-V Of Apitoria Pharma Private Limited A Wholly Owned Subsidiary Of The Company",
            "news_body": "Intimation of completion of US FDA inspection at Unit-V of Apitoria Pharma Private Limited a wholly owned subsidiary of the Company.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bc7a73b9-b60d-40af-8134-ba6d35192023.pdf",
            "news_date": "2025-12-12 17:13:38"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Submission of notice published in newspapers.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=99b85deb-3151-4fda-bf79-205ec63fdc11.pdf",
            "news_date": "2025-12-02 11:13:23"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Submission of newspaper publication.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5899a6c0-da27-490a-9351-276b31a9671c.pdf",
            "news_date": "2025-11-27 12:09:19"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Completion Of US FDA Inspection At Unit II Of Eugia Pharma Specialities Ltd. Bhiwadi A Wholly Owned Subsidiary Of The Company",
            "news_body": "Intimation of completion of US FDA inspection of Unit II of Eugia Pharma Specialities Limited Biwadi a wholly owned subsidiary of the Company.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c853a72d-861e-403d-9572-48770fc03e46.pdf",
            "news_date": "2025-11-14 16:06:44"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of investors meeting.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f6d8b817-5fb3-458a-b8b4-2284bfbb0b69.pdf",
            "news_date": "2025-11-14 11:49:34"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Classification Of US FDA Inspection At Unit-I Of Apitoria Pharma Private Limited A Wholly Owned Subsidiary Of The Company As Voluntary Action Indicated (VAI)",
            "news_body": "Intimation of classification of US FDA inspection at Unit-1 of Apitoria Pharma Private Limited.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=538d2430-bc76-4827-8444-84a7a32d3b2c.pdf",
            "news_date": "2025-11-14 10:31:50"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Submission of earning call transcript.",
            "news_id": "c4f1f090-997c-48c1-ba7a-48f75184e7d1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=38fa1702-0014-46be-805a-43fd18f17cc1.pdf",
            "news_date": "2025-11-11 17:01:33",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Earnings Call Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Submission of earning call transcript.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=38fa1702-0014-46be-805a-43fd18f17cc1.pdf",
            "news_date": "2025-11-11 17:01:33"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Submission of newspaper publication of unaudited financial results.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=95da7afa-cf15-4e08-9ae5-ed7426430380.pdf",
            "news_date": "2025-11-07 14:14:16"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Press release on unaudited financial results for the second quarter and half year ended 30.09.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4d337a99-bd7f-4f2c-83b8-8f85b7c8884f.pdf",
            "news_date": "2025-11-05 20:03:49"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Presentation on Unaudited Financial Results of the Company for the second quarter and half year ended 30.09.2025",
            "news_id": "ae039f02-8dc5-4ca7-bced-b170229c336b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f3f251a0-a55f-47f8-88cf-8e712f9ff554.pdf",
            "news_date": "2025-11-05 20:00:09",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Presentation on Unaudited Financial Results of the Company for the second quarter and half year ended 30.09.2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f3f251a0-a55f-47f8-88cf-8e712f9ff554.pdf",
            "news_date": "2025-11-05 20:00:09"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On November 5 2025",
            "news_body": "The Board of Directors of the Company at its meeting held today November 5 2025 has inter alia considered and approved the standalone and consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30 2025 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. \r\n\r\nWe enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Reports issued by the Statutory Auditors. \r\n",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9f1743a7-c2b9-4435-aa73-d9177929537f.pdf",
            "news_date": "2025-11-05 19:52:10"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Management",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
            "news_body": "Announcement of change in Senior Management Personnel.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1f57c943-3a66-4a93-a2f7-617f841e2424.pdf",
            "news_date": "2025-11-04 12:57:01"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Clarification  With Reference To Movement In Volume.",
            "news_body": "Submission of clarification with reference to movement of volume.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dd9d547b-c3a4-4191-82e9-b1c73f93344e.pdf",
            "news_date": "2025-10-30 15:23:21"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General",
            "descriptor": "Clarification",
            "caption": "Clarification sought from Aurobindo Pharma Ltd",
            "news_body": "The Exchange has sought clarification from Aurobindo Pharma Ltd on October 30 2025 with reference to Movement in Volume. <BR><BR>The reply is awaited.",
            "file_url": "",
            "news_date": "2025-10-30 14:41:50"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of plant visit by investor group.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0a08e7c4-37da-42e3-8bc5-e67bd9760008.pdf",
            "news_date": "2025-10-28 10:39:16"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of the date of Earnings Call on Unaudited Financial Results of the Company for the second quarter and half year ended 30.09.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=95384015-daf6-43ca-924b-cad446dfdb5a.pdf",
            "news_date": "2025-10-28 10:36:59"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Intimation Of Board Meeting To Be Held On November 5 2025 For Consideration Unaudited Financial Results For The Second Quarter & Half Year Ended On September 30 2025.",
            "news_body": "Aurobindo Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2025 inter alia to consider and approve Intimation of Board meeting",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ff84eebd-d893-4114-ae40-a2e4c42a0f45.pdf",
            "news_date": "2025-10-24 16:05:30"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Acquisition",
            "caption": "Announcement under Regulation 30 (LODR)-Acquisition",
            "news_body": "Intimation of incorporation of a stepdown subsidiary viz Eugia Pharma Chile SpA in Chile.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d277e961-c6ba-413b-867d-2849c0b8b4b5.pdf",
            "news_date": "2025-10-23 09:53:41"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Acquisition",
            "caption": "Announcement under Regulation 30 (LODR)-Acquisition",
            "news_body": "Intimation of incorporation of a step-down subsidiary viz. Aurobindo Pharma Chile SpA in Chile.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d3be9bc0-abd3-4a18-aefc-b81118366a11.pdf",
            "news_date": "2025-10-23 09:49:22"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Submission of notice published in newspapers regarding relodgement of transfer requests of physical shares.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6df3419c-2fde-42dd-8301-6bfb061006e6.pdf",
            "news_date": "2025-10-16 12:51:11"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "Submission of certificate under Regulation 74(5) of SEBI (DP) Regulations 2018",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c6a4f985-cf3d-4a71-93c7-2a4ad925185f.pdf",
            "news_date": "2025-10-07 18:20:40"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Management",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
            "news_body": "Intimation of resignation of Mr. S. Venkatesh Kumar as Associate Vice President Engineering Purchases.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=12661919-e970-4ca4-8590-d83c8d5e8418.pdf",
            "news_date": "2025-10-01 12:19:19"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Acquisition",
            "caption": "Announcement under Regulation 30 (LODR)-Updates on Acquisition",
            "news_body": "Intimation of completion of transfer of shares among subsidiary companies.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=39be82e1-d755-4880-b5c6-5ee205d9b2cc.pdf",
            "news_date": "2025-10-01 12:00:35"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Acquisition",
            "caption": "Announcement under Regulation 30 (LODR)-Acquisition",
            "news_body": "Intimation of incorporation of CuraTeQ Biologics (Malta) Limited a new wholly owned stepdown subsidiary.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a0c75ab4-9210-4dc5-80dc-ebdf532b6906.pdf",
            "news_date": "2025-09-26 18:14:37"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Acquisition",
            "caption": "Announcement under Regulation 30 (LODR)-Updates on Acquisition",
            "news_body": "Update on transfer of shares among subsidiary companies.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=58a16557-f090-4a5d-a9be-204c964202d9.pdf",
            "news_date": "2025-09-26 17:30:16"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Acquisition",
            "caption": "Announcement under Regulation 30 (LODR)-Updates on Acquisition",
            "news_body": "Update on acquistion of 26% stake in Swarnaakshu Solar Power Private Limited.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=46f2b148-2d19-4ab2-a022-1c4ffc48bd61.pdf",
            "news_date": "2025-09-26 15:54:53"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "Intimation of closure of trading window.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=83c8397f-3826-4295-8177-d5c8081594dc.pdf",
            "news_date": "2025-09-24 12:32:15"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Fire Accident At Unit-IV Of APL Healthcare Limited A Wholly Owned Subsidiary Of The Company",
            "news_body": "Intimation of fire accident at Unit 4 of APL Healthcare Limited a wholly owned subsidiary of the Company.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2163926a-c343-4482-8653-13ddde9f2759.pdf",
            "news_date": "2025-09-19 13:24:25"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Curateq Biologics Announces Successful Completion Of Phase 3 Clinical Study For Denosumab Biosimilar.",
            "news_body": "Submission of disclosure of successful of phase 3 clinical study for Denosumab Biosimilar by CuraTeQ Biologics Private Limited a wholly owned subsidiary of the Company.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9e0f851f-c59c-40e6-80ac-f25fd0ab4cfa.pdf",
            "news_date": "2025-09-19 10:19:19"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.",
            "news_body": "Intimation of incorporation of a wholly owned step-down subsidiary in Malaysia.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a3a18ea2-0cca-46d0-9fe2-404106d13a14.pdf",
            "news_date": "2025-09-17 17:24:28"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Clarification On Significant Volume Movement In CompanyS Shares",
            "news_body": "Submission of Clarification Letter on significant movement in Volume of shares",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5787cc75-3033-4226-ae11-dce6bd23ce64.pdf",
            "news_date": "2025-09-12 14:25:20"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General",
            "descriptor": "Clarification",
            "caption": "Clarification sought from Aurobindo Pharma Ltd",
            "news_body": "The Exchange has sought clarification from Aurobindo Pharma Ltd on September 12 2025 with reference to Movement in Volume. <BR><BR>The reply is awaited.",
            "file_url": "",
            "news_date": "2025-09-12 13:21:25"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "Outcome",
            "descriptor": "AGM",
            "caption": "Shareholder Meeting / Postal Ballot-Scrutinizers Report",
            "news_body": "Submission of Voting Results of 38th AGM along with Scrutinizer Report.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1f0db7a9-ffa6-4ff8-b8c0-1a9e7f4a1da3.pdf",
            "news_date": "2025-09-11 17:33:13"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "Outcome",
            "descriptor": "AGM",
            "caption": "Shareholder Meeting / Postal Ballot-Outcome of AGM",
            "news_body": "Submission of Proceedings of 38th AGM of the Company held on September 10 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d88fe195-bfad-4a67-b662-e460f05153bc.pdf",
            "news_date": "2025-09-10 17:52:18"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Completion Of US FDA Inspection At Unit-XII Of Aurobindo Pharma Limited",
            "news_body": "Intimation of completion of US FDA Inspection at Unit-XII of Aurobindo Pharma Limited",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c0b6111a-df67-456c-be19-06c427e10fcf.pdf",
            "news_date": "2025-09-05 18:41:47"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Submission of notice published in newspapers.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9e91e8df-4346-41c0-9025-b92c47886dfb.pdf",
            "news_date": "2025-09-02 11:35:02"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Completion Of US FDA Inspection At Unit-I Of Apitoria Pharma Private Limited A Wholly Owned Subsidiary Of The Company",
            "news_body": "Intimation of Completion of US FDA inspection at Unit-1 of Apitoria Pharma Private Limited a wholly owned subsidiary of the Company.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a6e05875-fc08-4dea-a591-1fabbaa45af1.pdf",
            "news_date": "2025-08-29 22:03:22"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Acquisition",
            "caption": "Announcement under Regulation 30 (LODR)-Updates on Acquisition",
            "news_body": "Update on entering into a binding agreement for transfer of shares of Curateq Biologics s.r.o by Helic Healthcare B.V to Curateq Biologics B.V wholly owned subsidiaries of the Company.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1b27c2ff-59ea-42fd-b336-d56806bb1f65.pdf",
            "news_date": "2025-08-29 16:02:21"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of investor meeting on 04.09.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=454b4890-d646-4b91-b0d7-65f6512a1f4c.pdf",
            "news_date": "2025-08-29 12:06:38"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of investor meeting on 03.09.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7132ded3-5294-48bb-95db-f953e72dfca7.pdf",
            "news_date": "2025-08-29 12:03:31"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Curateq Biologics S.R.O A Wholly Owned Step-Down Subsidiary Of The Company Receives Approval For Biosimilar Dazublys From UKS MHRA",
            "news_body": "Intimation of receipt approval for biosimilar Dazyblys from UKs MHRA by Curateq Biologics s.r.o a wholly owned step-down subsidiary of the Company.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b75229da-a670-4ac6-a0af-05437f07407b.pdf",
            "news_date": "2025-08-26 09:40:44"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Submission of notice published in newspapers regarding IEPFA 100 days campaign \"Saksham Niveshak\".",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d11bddec-f44d-47ba-a6a9-41ac38b4cdc3.pdf",
            "news_date": "2025-08-20 11:56:19"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "GENERAL",
            "caption": "Rumour verification - Regulation 30(11)",
            "news_body": "Submission of clarification on news item appearing in media titled \"Aurobindo closing in on $5.5 billion Zentiva Buyout.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5a40d897-0b16-4a33-afa6-23e41535fdfe.pdf",
            "news_date": "2025-08-20 11:13:00"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements)\r\nRegulations 2015",
            "news_body": "Confirmation of dispatch of letters to shareholders who have not registered their email ids  providing weblink for Integrated Annual Report 2024-25.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=060a66e9-87bd-46b3-bcd5-184f039e6c0c.pdf",
            "news_date": "2025-08-19 17:58:55"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Submission of news paper publications.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8fbaf623-acc5-4c99-a535-b4fac7d96543.pdf",
            "news_date": "2025-08-15 11:11:22"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Business Responsibility and Sustainability Reporting (BRSR)",
            "caption": "Business Responsibility and Sustainability Reporting (BRSR)",
            "news_body": "Submission of Business Responsibility and Sustainability Report for the Financial Year 2024-25",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fe003309-4ba7-48dd-9879-f77c9134d49a.pdf",
            "news_date": "2025-08-14 15:52:19"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "Intimation",
            "descriptor": "AGM",
            "caption": "Notice Of 38Th Annual General Meeting Scheduled To Be Held On September 10 2025",
            "news_body": "Submission of Notice of 38th Annual General Meeting",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=52e9edcf-3ac0-4316-a264-18489371cf59.pdf",
            "news_date": "2025-08-14 15:41:21"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Reg. 34 (1) Annual Report",
            "caption": "Reg. 34 (1) Annual Report.",
            "news_body": "Submission of Integrated Annual Report for the Financial Year 2024-25",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0e3a5b88-6f3b-4a5d-8d07-7186fd4b1f25.pdf",
            "news_date": "2025-08-14 15:22:52"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of investor meeting to be held on August 20 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f0c763e0-8dd9-42a3-99b4-3125fad157ca.pdf",
            "news_date": "2025-08-12 18:11:13"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "AGM",
            "caption": "Intimation Of 38Th Annual General Meeting Of Aurobindo Pharma Limited.",
            "news_body": "Intimation of 38th Annual General Meeting of the Company to be held on September 10 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e0050817-4f4a-4da3-b93a-51fc03212d70.pdf",
            "news_date": "2025-08-12 11:57:40"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Submission of transcript of earnings call on the Unaudited Financial Results for the first quarter ended June 30. 2025.",
            "news_id": "4b6e84e5-f88d-458a-a4b4-affe6bae40d6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cba3da3b-6c58-4ea1-99f1-5853086d9a8a.pdf",
            "news_date": "2025-08-08 12:07:00",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Earnings Call Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Submission of transcript of earnings call on the Unaudited Financial Results for the first quarter ended June 30. 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cba3da3b-6c58-4ea1-99f1-5853086d9a8a.pdf",
            "news_date": "2025-08-08 12:07:00"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Submission of newspaper advertisement of Unaudited Financial Results of the Company for the first quarter ended June 30 2025 as published in Business Standard and Nava Telangana on August 6 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fbd3aad3-17e0-4708-bad3-757cbf6db81a.pdf",
            "news_date": "2025-08-06 12:08:50"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Submission of Press release  on unaudited Financial Results for the first quarter ended June 30 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e6f3a9ef-5218-4f6a-8003-c21941c6a8d9.pdf",
            "news_date": "2025-08-04 19:51:05"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Submission of Investor Presentation that would be used in the investors/analyst call on unaudited financial results of the Company for the first quarter ended June 302025",
            "news_id": "8f070f2a-1da3-4ec2-8944-b30faefae25d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8315ee0f-ddb9-4da4-808f-ca32938618e5.pdf",
            "news_date": "2025-08-04 19:46:17",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Submission of Investor Presentation that would be used in the investors/analyst call on unaudited financial results of the Company for the first quarter ended June 302025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8315ee0f-ddb9-4da4-808f-ca32938618e5.pdf",
            "news_date": "2025-08-04 19:46:17"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "Intimation",
            "descriptor": "Record Date",
            "caption": "Intimation Of Record Date For Payment Of Interim Dividend For The FY 2025-26",
            "news_body": "Intimation of Record Date for payment of Interim Dividend for the FY 2025-26",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b872e20f-f181-4d87-b19a-69674fd289fe.pdf",
            "news_date": "2025-08-04 19:40:11"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "Outcome",
            "descriptor": "Dividend",
            "caption": "Corporate Action-Board approves Dividend",
            "news_body": "The Board of Directors of the company at its meeting held today August 4 2025 has approved the payment of Interim Dividend of  400%  i.e Rs.4.00 (Rupees Four Only) per equity share of Rs.1. /- each on equity share capital of the company The Company has fixed  August 8 2025  as the record date for purpose of the payment of interim Dividend and the same will paid on or before August 21 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3a104934-b55d-4e9b-91ab-17bf663a12f9.pdf",
            "news_date": "2025-08-04 19:36:18"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On August 4 2025",
            "news_body": "The Board of Directors of the Company at its meeting held today August 4 2025 has inter alia considered and approved: -\r\n\r\n1. the standalone and consolidated Unaudited Financial Results of the Company for the first quarter ended June 30 2025 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Reports issued by the Statutory Auditors. \r\n\r\n2.  the payment of interim dividend of 400% i.e. Rs.4.00 (Rupee Four only) per equity share of Re.1/- each on the equity share capital of the Company. The Company has fixed August 8 2025 as the Record Date for the purpose of payment of Interim Dividend and the same will be paid on or before August 21 2025.\r\n",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dd3e24d6-efee-4b4f-a7ae-6eb284961b63.pdf",
            "news_date": "2025-08-04 19:26:50"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Clarification On News Item Appearing In Media/Publication",
            "news_body": "Submission of clarification on news items appearing in Media.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=512bb3c4-69ac-49d0-a7d8-c37f86351717.pdf",
            "news_date": "2025-08-01 14:43:24"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General",
            "descriptor": "Clarification",
            "caption": "Clarification sought from Aurobindo Pharma Ltd",
            "news_body": "The Exchange has sought clarification from Aurobindo Pharma Ltd on August 1 2025 with reference to news appeared in https://www.moneycontrol.com dated August 1 2025 quoting \"Pharma stocks slump as Trump shoots letters to 17 global drug majors seeking lower prices\".<BR><BR>The reply is awaited.",
            "file_url": "",
            "news_date": "2025-08-01 13:28:46"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Acquisition",
            "caption": "Announcement under Regulation 30 (LODR)-Acquisition",
            "news_body": "Intimation of acquisition of Lannett Company LLC USA by Aurobindo Pharma USA Inc a wholly owned subsidiary of the Company",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e1838f86-ef1b-41f7-865b-28ff7ca82fec.pdf",
            "news_date": "2025-07-30 19:41:47"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Acquisition",
            "caption": "Announcement under Regulation 30 (LODR)-Acquisition",
            "news_body": "Intimation of entering into binding agreement for transfer of shares of Curateq Biologics s.r.o.  by Helix Healthcare B.V to Curateq Biologics B.V. wholly owned subsidiaries of the Company",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=04a1ce78-cc66-4436-a7eb-58c118d80aa3.pdf",
            "news_date": "2025-07-30 17:29:29"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of Earnings Call to be held on August 5 2025 at 8:30 AM (IST) on Unaudited Financial Results of the Company for the first quarter ended June 30 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=091fb05a-d976-42e5-8e55-9d6d44451775.pdf",
            "news_date": "2025-07-24 12:09:45"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Intimation Of Board Meeting For Consideration Of Unaudited Financial Results And Dividend",
            "news_body": "Aurobindo Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2025 inter alia to consider and approve Intimation of Board Meeting for consideration of unaudited Financial Results for the quarter ended June 30 2025 and Dividend.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=93ab65a6-01de-44a0-a27f-500efff0e1bd.pdf",
            "news_date": "2025-07-23 16:30:36"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Submission of copies of notice published in newspapers regarding special window for re-lodgement of transfer requests of physical shares.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=62a0f78f-9965-446d-8e57-1cfd59657851.pdf",
            "news_date": "2025-07-23 12:24:41"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "Submission of Certificate in terms of Regulation 74 (5) of SEBI (Depositories and Participants) Regulations 2018  for the quarter ended June 30 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b5b6c7cb-6081-4c2d-a054-a8b9e53ada63.pdf",
            "news_date": "2025-07-03 11:31:51"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Restructuring",
            "caption": "Announcement under Regulation 30 (LODR)-Restructuring",
            "news_body": "Intimation of merger of a wholly owned subsidiary with another wholly owned subsidiary.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=67107eea-d49d-4493-9ebd-2dfd8ab20ba0.pdf",
            "news_date": "2025-07-02 18:27:54"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Curateq Biologics Receives Marketing Approval For Trastuzumab Biosimilar Dazublys\u2122 From European Commission",
            "news_body": "Intimation of receipt of marketing approval for trastuzumab biosimilar Dazublys from European Commission by Curateq Biologics s.r.o a wholly owned step down subsidiary of the Company.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=642bdc6b-52c6-473f-9906-6b10dfd54e3f.pdf",
            "news_date": "2025-07-02 16:54:15"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "Acquisition",
            "caption": "Announcement under Regulation 30 (LODR)-Updates on Acquisition",
            "news_body": "Updation on acquisition 26% stake in Swarnaakshu Solar Powar Private Limited.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=adcbf75a-017a-42b4-893a-fe1961b0ccfd.pdf",
            "news_date": "2025-06-30 16:17:16"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Restart Of Penicillin-G Production At Our Kakinada Facility Post Receipt Of Consent To Operate From Andhra Pradesh Pollution Control Board",
            "news_body": "Intimation of restart of Pencillin-G production at our Kakinada facility post receipt of Consent to Operate from Andhra Pradesh Pollution Control Board.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=565c3d54-0f63-4183-9791-c778178583e3.pdf",
            "news_date": "2025-06-29 16:44:33"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "Intimation of closure of Trading window for the Unaudited Financial Results for the First Quarter ending on June 30 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fc6856cd-073d-4bfe-a087-0748f64497f0.pdf",
            "news_date": "2025-06-26 10:32:12"
        },
        {
            "co_code": 4666,
            "bse_code": 524804,
            "isin": "INE406A01037",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Curateq Biologics S.R.O A Wholly Owned Step-Down Subsidiary Of The Company Receives Approval For Biosimilar Dyrupeg From UKS MHRA",
            "news_body": "Intimation of receipt of approval for biosimilar Dyrupeq from UKs MHRA by Curateq Biologics s.r.o a wholly owned step down subsidiary of the Company.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4818e0f8-1b19-4799-b97a-cd953b20564b.pdf",
            "news_date": "2025-06-24 16:54:00"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Submission of earning call transcript .",
            "news_id": "19a2d8ea-7567-4f73-8e38-4d3963791b4e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=18df2504-0212-4327-971e-954b70abb3bf.pdf",
            "news_date": "2025-06-02 16:57:00",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Submission of Earnings Presentation on Audited Financial Results for the quarter and year ended March 31 2025.",
            "news_id": "9a810ebb-66e6-44e7-abc4-88db31491033",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=052022b5-95e0-45ba-bf01-6c1db76b5d9f.pdf",
            "news_date": "2025-05-26 20:08:06",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Submission of Q3 of FY2025 earnings call  transcript",
            "news_id": "a99c94e6-e6ed-4dea-a9cf-8f05302496e0",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7a1fdc43-c10e-460c-a60f-512ed9cd4218.pdf",
            "news_date": "2025-02-13 12:05:21",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Submission of Investor Presentation",
            "news_id": "3e469fcd-11f1-49c0-b344-836788df4b7d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3de8a0cf-c364-4b5e-b51b-03e67ce5e338.pdf",
            "news_date": "2025-02-06 20:22:43",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Nine Months Period Ended December 31 2024",
            "news_body": "submission of Unaudited financial results for the quarter and nine months period ended December 31 2024",
            "news_id": "453e48e5-b79c-437a-b037-890a0629f9a1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b4858ffa-bfde-4404-aeeb-3490d94ee738.pdf",
            "news_date": "2025-02-06 19:56:52",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Submission of Transcript of Earnings Call on Unaudited financial Results for the Quarter and Half Year ended  30th September 2024.",
            "news_id": "91f45d47-c400-46b1-a9a8-75591bbfb4e9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5216098b-a943-44ca-a1ab-72094c7f334c.pdf",
            "news_date": "2024-11-18 11:07:10",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of SEBI Listing Regulations, and further to our letter dated November 4, 2024, please note that the audio recording of the earnings call on the Unaudited Financial Results for the second quarter and half year ended September 30, 2024, held on November 11, 2024 at 8.30 AM (IST), has been uploaded on our website on the following web-link:https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/audio-or-video-recordings",
            "news_id": "212a14fc-08be-4e2a-9ee7-a712752023c7",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=87f24c7f-72f4-461e-b38e-153d9e7c0b68.pdf",
            "news_date": "2024-11-11 15:08:05",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Half Year Ended September 30,2024",
            "news_body": "Submitting the Unaudited Financial Results for the quarter and half year ended September 30, 2024",
            "news_id": "12729d3a-79c1-44e3-83f0-ee65adfe0d50",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cf565e81-c3f3-45e8-9586-5c9e45810c1e.pdf",
            "news_date": "2024-11-09 19:13:33",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "We enclose the presentation on Unaudited Financial Results for the quarter and half year ended September 30, 2024",
            "news_id": "098c2abc-cd46-4996-b861-9b8f9a6a0fa7",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=09f46763-3228-4857-a164-39bea5713450.pdf",
            "news_date": "2024-11-09 19:07:26",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Submission of Transcript of Earning call on unaudited financial results of Q1 2024-25.",
            "news_id": "5209be2a-706a-4afa-ba09-88347b757dcd",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2fa5dd59-59af-4bda-af84-37083f4141c5.pdf",
            "news_date": "2024-08-16 15:13:46",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of SEBI Listing Regulations, and further to our letter dated August 5, 2024, please note that the audio recording of the earnings call on the Unaudited Financial Results for the first quarter ended June 30, 2024, held on August 12, 2024, at 8.30 AM (IST), has been uploaded on our website on the following web-link:https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/audio-or-video-recordings",
            "news_id": "c06b7932-b541-47db-954b-4d54121ec358",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=be0eb07c-3a93-4133-96e4-2267ab87f265.pdf",
            "news_date": "2024-08-12 15:14:23",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Submission of Investor Presentation on Unaudited Financial Results for Q1 of FY 2024-25.",
            "news_id": "1290bb46-607a-40a1-a438-e62c405285c6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=85e2064d-1ff4-4242-8f5a-1a8f7cbd0008.pdf",
            "news_date": "2024-08-10 18:45:33",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Submission Of Unaudited Financial Results For The 1St Quarter Of FY 2024-25",
            "news_body": "Submission of Unaudited Financial Results for the 1st Quarter of FY 2024-25",
            "news_id": "fccf0113-0630-4ca2-baed-c7dd34b22c9b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5e7a039b-972f-487b-95d0-cc4b16667232.pdf",
            "news_date": "2024-08-10 18:33:21",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Submission of transcript of earnings call held on May 27, 2024 on audited financial results for the fourth quarter and year ended on March 31, 2024.",
            "news_id": "7d76d78d-19db-4c65-aa50-1438467cd54f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fefdeb36-1743-418d-a02e-7f05451a69b3.pdf",
            "news_date": "2024-05-31 18:29:03",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Submission of Audio recording of earnings call held on 27th May 2024 on Audited Financial Results for the year ended 31st March 2024.",
            "news_id": "f743e809-d2a0-4c34-90cf-2dd850a1611d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d34977e0-1615-4406-9e54-5fccad598fff.pdf",
            "news_date": "2024-05-27 16:36:04",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Submission of Investors Presentation on audited financial results for the financial year ended March 31, 2024",
            "news_id": "21a03e9a-f534-40ee-a893-be4de4496b0e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=954eae16-10a4-457a-bc5a-9a6f36765cd6.pdf",
            "news_date": "2024-05-25 19:20:56",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For The Fourth Quarter And Financial Year Ended March 31, 2024",
            "news_body": "Submission of Audited Financial Results for the fourth quarter and financial year ended on March 31, 2024",
            "news_id": "32cac090-d4aa-484b-8b8c-ecb7ca460c8e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a3848890-121a-4ed6-843b-9060ee78da91.pdf",
            "news_date": "2024-05-25 19:01:30",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Weblink of Investor Presentation",
            "news_id": "5e55e5fa-e3e8-4286-bdaf-aeb670248992",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=68a574d2-96b6-4657-9123-ad4fdbcac35c.pdf",
            "news_date": "2024-03-13 11:31:56",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Submission of Earnings Call Transcript on Q3 FY2023-24",
            "news_id": "08cda593-1595-42d4-a4e5-9b00c5d66749",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=06a705ce-0ecd-42a2-bb8e-6750a29e8330.pdf",
            "news_date": "2024-02-16 15:21:29",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio recording of Earnings Call held on 12th February 2024 on Q3FY24 Unaudited Financial Results",
            "news_id": "c5b63eff-4d31-4bb7-a70d-cb070638346b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5d809f63-348a-479d-9374-7c2b35b90cb7.pdf",
            "news_date": "2024-02-12 12:45:22",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation on Unaudited Financial Results for the quarter and nine months period ended on 31st December 2023",
            "news_id": "abb91e91-ece7-456a-a181-cfece7e8da77",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b61725fe-095c-49a9-8a0d-b24dc2790adf.pdf",
            "news_date": "2024-02-10 18:12:49",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For The Quarter Ended 31St December 2023",
            "news_body": "Submission of Financial Results for the quarter and nine months period ended 31st December 2023",
            "news_id": "53f5258b-b09f-49de-9d82-5bf07db15ad1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4c3eefd9-9115-41d0-b85e-c887c6a927aa.pdf",
            "news_date": "2024-02-10 17:41:36",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Intimation Of Outcome Of Board Meeting Held Today, February 10, 2024",
            "news_body": "Intimation of outcome of Board meeting held on February 10, 2024",
            "news_id": "d67086e4-ce86-4523-bdb2-f6546451b1cd",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f9eeec9a-7a60-42a9-b79f-5a948864135a.pdf",
            "news_date": "2024-02-10 17:35:27",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of Q2FY24 Earnings Call held on November 10, 2023",
            "news_id": "e9eac057-4ba4-47d3-9159-4d53898fa90e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0f332acf-b597-4c44-bc68-5d76f0f2e8de.pdf",
            "news_date": "2023-11-15 12:57:07",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter Ended 30Th September 2023.",
            "news_body": "Unaudited Financial Results for the quarter ended 30th September 2023.",
            "news_id": "e462b54c-5176-41e1-911c-677003b49d97",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b9124436-aaa0-4139-94f9-468bf34bb532.pdf",
            "news_date": "2023-11-09 19:52:07",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Earning Presentation on Q2FY24 Unaudited Financial Results",
            "news_id": "42baf8e8-9691-44b5-b08d-341f1939f24c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=49b09f51-72b3-4b61-86f1-681a090021a4.pdf",
            "news_date": "2023-11-09 19:46:54",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Please find attached the earning call transcript for the quarter ended June 30, 2023.",
            "news_id": "004a0edb-8652-4116-ace4-dc6e7b0b4f67",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c652426c-06f6-4edf-bedf-8f5cd0466ef0.pdf",
            "news_date": "2023-08-18 12:45:38",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of SEBI Listing Regulations, and further to our letter dated August 4, 2023, please note that the audio recording of the earnings call on the unaudited financial results for the first quarter ended June 30, 2023, held on August 14, 2023, at 8.30 AM (IST), has been uploaded on our website on the following web-link:https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/audio-or-video-recordings/",
            "news_id": "0b9fcc1c-8989-4e65-a4f3-e4246f36a82e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5f94176f-de7c-4de3-982b-cefc8ac69c99.pdf",
            "news_date": "2023-08-14 13:09:08",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation on un-audited financial results for the first quarter ended June 30, 2023.",
            "news_id": "a7528efc-6c2f-4f09-8959-ede1d28d6a3b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1f63e36d-fb67-4bf0-97e7-f918e0a580fa.pdf",
            "news_date": "2023-08-12 18:32:59",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Un-Audited Financial Results For The Quarter Ended June 30, 2023.",
            "news_body": "Un-audited financial results for the quarter ended June 30, 2023.",
            "news_id": "80cefc4d-e658-401c-96c0-794689b6ac06",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d663cb09-bb88-4b56-80f6-9651ff77c41f.pdf",
            "news_date": "2023-08-12 18:26:47",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Please refer to our letter dated May 19, 2023, wherein we intimated about the schedule of Investors/ Analysts call onMay 29, 2023. We are attaching herewith the Transcript of the said analyst / investor call on the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2023, and the same is being uploaded on the website of the Company and is available in the following web link.https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/conference-call-transcripts/",
            "news_id": "83421466-b761-43ea-bb22-f1ff22aa4105",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c1598e6b-722b-44cb-97b1-4c0324acbdc8.pdf",
            "news_date": "2023-06-01 16:16:40",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of SEBI Listing Regulations, and further to our letter dated May 19, 2023, please note that the audio recording of the earnings call on the audited financial results for the fourth quarter and year ended March 31, 2023, held on May 29, 2023, at 8.30 AM (IST), has been uploaded on our website on the following web-link:https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/audio-or-video-recordings/",
            "news_id": "9ba1ef0c-e815-4a3d-b9a8-64f88648b368",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=90aec6e5-4037-4d79-b19c-7b5d273ab435.pdf",
            "news_date": "2023-05-29 15:13:07",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please refer to our letter dated May 19, 2023 wherein we intimated the schedule of Investors/ Analysts call on May 31, 2023.  In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2023.  The presentation is also being uploaded in the following weblink of the Company.",
            "news_id": "42475dd9-86d9-4dac-a3a0-094f411e30b1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5c9ab1fc-bb0b-4148-ae91-5c1ccd9ecabc.pdf",
            "news_date": "2023-05-27 19:41:49",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For Mar 31, 2023",
            "news_body": "The Board of Directors of the Company at its meeting held today, May 27, 2023, has inter alia, considered andapproved the standalone and consolidated Audited Financial Results of the Company for the fourth quarter and yearended March 31, 2023, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015. We enclose herewith the said Audited Financial Results of the Company along with the AuditReports issued by the Statutory Auditors of the Company.Pursuant to Regulation 33(3)(d) of SEBI Listing Regulations, we hereby confirm and declare that the Statutory Auditorsof the Company, M/s. Deloitte Haskins & Sells, Chartered Accountants, have issued the audit reports on Standaloneand Consolidated Financial Results of the Company for the fourth quarter and year ended March 31, 2023, withunmodified opinion.",
            "news_id": "6b465205-1790-451a-aca1-5e659ffaf169",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4dc4d484-1e8e-4b5d-8477-eb90abd4ae72.pdf",
            "news_date": "2023-05-27 19:32:43",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of Q3 FY23 earnings call",
            "news_id": "e8b9481b-7033-4af1-b730-a6e80b53aa8c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0af27d5c-28a1-459e-b1ac-5782965241c4.pdf",
            "news_date": "2023-02-17 14:29:49",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of SEBI Listing Regulations, and further to our letter dated February 3, 2023, please note that the audio recording of the earnings call on the unaudited financial results for the third quarter and nine months period ended December 31, 2022, held on February 10, 2023, at 8.30 AM (IST), has been uploaded on our website on the following web-link:https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/audio-or-video-recordings/",
            "news_id": "26eabc6e-1cc9-45c6-9afc-f0535ad68ee2",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c219ebc5-51dd-47ae-9806-7b60aeb480b4.pdf",
            "news_date": "2023-02-10 16:08:52",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor presentation on Q3 - 2022-23 earnings.",
            "news_id": "31924097-f484-4684-af6a-27771bf2f52f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=03756010-91f3-4aa6-aac2-9b29d33253c7.pdf",
            "news_date": "2023-02-09 19:58:20",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Aale And Transfer Of Units Constituting API Non-Antibiotic Division Of The Company To Auro Pharma India Private Limited, A Wholly Owned Subsidiary Of The Company",
            "news_body": "Please refer to our letter dated February 3, 2023 wherein we have intimated the schedule of Investors/ Analysts call on February 10, 2023.  In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the Third quarter and nine months period ended December 31, 2022.  The presentation is also being uploaded in the following weblink of the Company.https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/presentations/",
            "news_id": "77b194bb-70e1-4e01-a36e-82db687eb603",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7a9a78e3-2d6f-4af4-9d91-93f288d7cbed.pdf",
            "news_date": "2023-02-09 19:32:23",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Aale And Transfer Of Units Constituting API Non-Antibiotic Division Of The Company To Auro Pharma India Private Limited, A Wholly Owned Subsidiary Of The Company",
            "news_body": "Please refer to our letter dated February 3, 2023 wherein we have intimated the schedule of Investors/ Analysts call on February 10, 2023.  In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the Third quarter and nine months period ended December 31, 2022.  The presentation is also being uploaded in the following weblink of the Company.https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/presentations/",
            "news_id": "8c7499b9-b1d7-42b0-8ecc-052cb1eda285",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9d3f7a93-f47b-44d5-b5b5-aabf047e54c4.pdf",
            "news_date": "2023-02-09 19:19:58",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Nine Months Period Ended 31.12.2022",
            "news_body": "The Board of Directors of the Company at its meeting held today, February 9, 2023, has inter alia, transacted the following items of business:<BR> <BR> 1.  Approved the standalone and consolidated Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2022, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors.<BR> <BR> 2.  Approved first interim dividend of 300% i.e. Rs.3.00 (Rupees three only) per equity share of Re.1/- each on the equity share capital of the Company. The Company has already fixed February 17, 2023 as the record date for the purpose of payment of interim dividend for the financial year 2022-23. The interim dividend will be paid on or before March 3, 2023.<BR> <BR>",
            "news_id": "7fda3a54-46a6-40a8-a269-b6255a97275a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b2eed77e-6f8c-4063-a22f-037420f6fb7a.pdf",
            "news_date": "2023-02-09 18:51:21",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions For The Half Year Ended 30Th September 2022",
            "news_body": "Pursuant to Regulation 23(9) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith disclosure on Related Party Transactions for the half year ended September 30, 2022.The above disclosure is also being updated on the Company's website www.aurobindo.com",
            "news_id": "19c93104-5ab9-43a9-b200-3eb06bad6752",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8f10ac60-fda7-4da7-acf8-2e7e58fa850f.pdf",
            "news_date": "2022-11-25 23:40:26",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions For The Half Year Ended 30Th September 2022",
            "news_body": "Pursuant to Regulation 23(9) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith disclosure on Related Party Transactions for the half year ended September 30, 2022. The above disclosure is also being updated on the Company's website www.aurobindo.com",
            "news_id": "4f9330ee-5e98-44a1-8e53-83e3cd4aef36",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=27e6ac98-66f7-419f-b179-ed51cd5ad05d.pdf",
            "news_date": "2022-11-25 23:34:09",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Sub: Transcript of Q2FY23 earnings call.Please refer to our letter dated November 8, 2022 wherein we intimated about the schedule of Investors/ Analysts call on November 14, 2022. We are attaching herewith the Transcript of the said analyst / investor call on the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2022 and the same is being uploaded on the website of the Company and is available in the following web link.https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/conference-call-transcripts/Please take the information on record.",
            "news_id": "eebb4ce6-c534-4484-8ca5-f38214ca562c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a7c69553-0feb-4b65-a2d1-3ec716f38c63.pdf",
            "news_date": "2022-11-18 16:23:37",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of SEBI Listing Regulations, and further to our letter dated November 8, 2022, please note that the audio recording of the earnings call on the unaudited financial results for the second quarter and half year ended September 30, 2022, held on November 14, 2022, at 8.30 AM (IST), has been uploaded on our website on the following web-link:https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/audio-or-video-recordings/",
            "news_id": "e7df7952-c571-4a42-8e8c-c2b79bb23c72",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=128d9461-3813-4aa1-91e4-436e37b3031c.pdf",
            "news_date": "2022-11-14 16:41:21",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please refer to our letter dated November 8, 2022 wherein we have intimated the schedule of Investors/ Analysts call on November 14, 2022. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the Second quarter and half year ended September 30, 2022.The presentation is also being uploaded in the following weblink of the Company.https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/presentations/",
            "news_id": "0023329c-c757-42ac-b4ba-f76c53b22a19",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2153e0d0-7afc-444f-8458-d866a4fbcbd2.pdf",
            "news_date": "2022-11-12 17:55:58",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Second Quarter And Half Year Ended 30.09.2022",
            "news_body": "The Board of Directors of the Company at its meeting held today, November 12, 2022, has, inter alia, considered and<BR> approved the Un-audited Financial Results of the Company for the Second Quarter and half year ended September<BR> 30, 2022 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.<BR> We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory<BR> Auditors of the Company.<BR> The Board meeting commenced at 2.30 p.m. and concluded at 5.05 p.m.",
            "news_id": "a10a8bda-43a3-4e6c-ab97-f5c23f931da5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c71d934e-0b76-4153-ad98-37a2bb4fcc19.pdf",
            "news_date": "2022-11-12 17:31:00",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Further to our letter dated September 6, 2022 informing about the participation in the Kotak Institutional Equity Healthcare Forum 2022 on September 8, 2022, we inform you that the presentation updated in the following weblink of the Company will be used during the interaction with the investors.https://www.aurobindo.com/wp-content/uploads/2022/09/Aurobindo-Pharma_Investor-Presentation_INR_Sep-22.pdfNo unpublished price sensitive information (UPSI) is intended to be discussed during the interactions.",
            "news_id": "d73310bd-06c7-410d-86a4-b737bc1d5f3b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8073fada-0372-4208-9207-3a8c04b0872f.pdf",
            "news_date": "2022-09-07 16:11:45",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Please refer to our letter dated August 8, 2022 wherein we have intimated the schedule of Investors/ Analysts call on August 12, 2022. We are attaching herewith the Transcript of the analyst / investor call on the Unaudited Financial Results of the Company for the first quarter ended June 30, 2022 and the same is being uploaded on the website of the Company and is available in the following web link.https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/",
            "news_id": "1b06c7bf-96f1-4eb8-b2ee-676545351532",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2121b890-a348-4e99-a006-d44e721e2756.pdf",
            "news_date": "2022-08-19 17:19:11",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "General",
            "cat": "Audio",
            "caption": "Audio Recording Of Earnings Call Conducted On August 12, 2022",
            "news_body": "Pursuant to Regulation 30 of SEBI Listing Regulations, and further to our letter dated August 8, 2022, please note that the audio recording of the earnings call  on the unaudited financial results for the first quarter ended June 30, 2022, held on August 12, 2022, at 8.30 AM (IST), has been uploaded on our website on the following web-link:https://www.aurobindo.com/wp-content/uploads/2022/08/audio1190421139.mp3",
            "news_id": "ca574ac7-de69-456c-a378-da032295b9ea",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=49c5f4cb-3b12-4133-86c6-d4a46740888c.pdf",
            "news_date": "2022-08-12 16:06:04",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please refer to our letter dated August 8, 2022 wherein we have intimated the schedule of Investors/ Analysts call on August 12, 2022.  In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the first quarter ended June 30, 2022.  The presentation is also being uploaded in the following weblink of the Company.https://www.aurobindo.com/investors/results-reports-presentations/results-announcements/",
            "news_id": "19dad558-05b7-49f1-9b99-aeb9b036af2f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=68697592-bf02-4c82-91c6-077e5e839ed3.pdf",
            "news_date": "2022-08-11 17:58:01",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter Ended June 30.2022",
            "news_body": "The Board of Directors of the Company at its meeting held today, August 11, 2022, has, inter alia, considered and approved the Un-audited Financial Results of the Company for the First Quarter ended June 30, 2022 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company.<BR> <BR> We also enclose a copy of the Press Release on the Un-audited Financial Results of the Company for the First Quarter ended June 30, 2022.",
            "news_id": "f56dba25-ff48-48cb-ae57-5d639c648928",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9e4207f3-3476-4372-972b-2c8a1d3f2c1c.pdf",
            "news_date": "2022-08-11 17:39:50",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions For The Half Year Ended March 31, 2022",
            "news_body": "Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed disclosure of Related Party Transactions for the half year ended March 31, 2022.",
            "news_id": "3b6877b5-15c0-468c-b471-c563cd59af93",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=80993276-f5d4-47e1-99ec-bc49805d6906.pdf",
            "news_date": "2022-06-14 16:56:34",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Please refer to our letter dated May 26, 2022 wherein we have intimated the schedule of Investors/ Analysts call on May 31, 2022. We are attaching herewith the Transcript of the analyst / investor call on the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2022 and the same is being uploaded on the website of the Company and is available in the following web link.https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/",
            "news_id": "88a0124d-8dfd-4e63-b382-acacc071f66f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b2d34ef9-ded8-4cdb-ab71-41718ce10034.pdf",
            "news_date": "2022-06-06 16:34:22",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "General",
            "cat": "Audio",
            "caption": "Audio Recording Of Earnings Call",
            "news_body": "Pursuant to Regulation 30 of SEBI Listing Regulations, and further to our letter dated May 26, 2022, please note that the audio recording of the earnings call for the fourth quarter and financial year ended March 31, 2022, held on May 31, 2022, at 8.30 AM (IST) has been uploaded on our website on the following web-link:https://www.aurobindo.com/wp-content/uploads/2022/05/Aurobindo-Q4-.mp3",
            "news_id": "91bbfa6b-a779-4da2-8d9f-885523673f04",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5a6167eb-4617-4bb7-9b26-8782fabac42c.pdf",
            "news_date": "2022-05-31 18:05:18",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Rsults For The Fourth Quarter And Year Ended 31.03.2022",
            "news_body": "The Board of Directors of the Company at its meeting held today, May 30, 2022, has inter alia, approved the standalone and consolidated Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2022, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Audited Financial Results of the Company along with the Auditors Report issued by the Statutory Auditors. Pursuant to Regulation 33(3)(d) of SEBI Listing Regulations, we hereby confirm and declare that the Statutory Auditors of the Company, M/s. B S R & Associates LLP, Chartered Accountants, have issued the audit report on Standalone and Consolidated Financial Results of the Company for the fourth quarter and year ended March 31, 2022, with unmodified opinion.<BR>",
            "news_id": "0488d934-31f7-4031-950a-7aba708f5c92",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e0c47650-484b-45eb-abf9-f7e53fc9df54.pdf",
            "news_date": "2022-05-30 20:32:59",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please refer to our letter dated May 26, 2022 wherein we have intimated the schedule of Investors/ Analysts call on May 31, 2022.  In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2022.  The presentation is also being uploaded in the following weblink of the Company.https://www.aurobindo.com/investors/results-reports-presentations/results-announcements/",
            "news_id": "9d76cb37-ce45-4bf6-99b6-e5783d90235f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ee34978c-fd37-4f28-9d9d-49f68e3dc7e2.pdf",
            "news_date": "2022-05-30 20:10:25",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Please refer to our letter dated February 3, 2022 wherein we have intimated the schedule of Investors/ Analysts call on February 10, 2022. We are attaching herewith the Transcript of the analyst / investor call on the Un-audited Financial Results of the Company for the third quarter and nine months period ended December 31, 2021 and the same is being uploaded on the website of the Company and is available in the following web link.https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/",
            "news_id": "44941360-b654-41a4-b48f-d402c9e03e70",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=abeeed9c-cd30-4a8b-8d4b-77fc0e90873d.pdf",
            "news_date": "2022-02-17 11:48:09",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please refer to our letter dated February 3, 2022 wherein we have intimated the schedule of Investors/ Analysts call on February 10, 2022.  In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the third quarter and nine months period ended December 31, 2021.  The presentation is also being uploaded in the following weblink of the Company.https://www.aurobindo.com/investors/results-reports-presentations/results-announcements/",
            "news_id": "9c763b61-b9c2-4dd1-855a-7b4f2fa33142",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=57af06ee-eacc-457c-a6b0-45398714c79d.pdf",
            "news_date": "2022-02-09 18:15:29",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Nine Months Period Ended 31.12.2021.",
            "news_body": "The Board of Directors of the Company at its meeting held today, February 9, 2022, has, inter alia,  considered and approved:- <BR> <BR> 1. the Un-audited Financial Results of the Company for the Third Quarter and nine months period ended December 31, 2021 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company; and<BR> <BR> 2.  a Third Interim Dividend @ 150% i.e. Rs.1.50 (Rupee one and paise fifty) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2021-22. The Company has fixed February 21, 2022 as the Record Date for the purpose of payment of Third Interim Dividend and the same will be paid on or before March 4, 2022. <BR>",
            "news_id": "2fed36e9-01b9-41e0-b279-9aecf084a050",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=97e3ecf2-aab3-4b8c-9120-21f831f5d921.pdf",
            "news_date": "2022-02-09 17:56:59",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Please refer to our letter dated November 2, 2021 wherein we have intimated the schedule of Investors/ Analysts call on November 9, 2021. We are attaching herewith the Transcript of the analyst / investor call on the Un-audited Financial Results of the Company for the second quarter and half year ended September 30, 2021 and the same is being uploaded on the website of the Company and is available in the following web link.<BR> <BR> https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/<BR>",
            "news_id": "4ba80d56-1284-406d-b141-e0673feef442",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=61038607-118e-4fc6-8d04-21e7bbb1f5b7.pdf",
            "news_date": "2021-11-19 15:08:33",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please refer to our letter dated November 2, 2021 wherein we have intimated the schedule of Investors/ Analysts call on November 9, 2021.  In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the second quarter and half year ended September 30, 2021.  The presentation is also being uploaded in the following weblink of the Company.",
            "news_id": "4c2791b7-5c2a-4704-b15c-b5f5d39f82dc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d2fb45cd-361e-46dd-981a-fd5e0f0b005e.pdf",
            "news_date": "2021-11-08 20:12:08",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Un-Audited Financial Results For The  Second Quarter And Half Year Ended September 30, 2021",
            "news_body": "The Board of Directors of the Company at its meeting held today, November 8, 2021, has, inter alia,  considered and approved the Un-audited Financial Results of the Company for the Second Quarter and half year ended September 30, 2021 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company; <BR>",
            "news_id": "7dd92742-4348-4d1c-bffa-3e82364fbbf8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a919a350-9a61-455f-9a11-0884b39acf6e.pdf",
            "news_date": "2021-11-08 19:37:46",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On November 8, 2021.",
            "news_body": "The Board of Directors of the Company at its meeting held today, November 8, 2021, has, inter alia,  considered and approved:- <BR> <BR> 1. the Un-audited Financial Results of the Company for the Second Quarter and half year ended September 30, 2021 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company;<BR> <BR> 2.  a Second Interim Dividend @ 150% i.e Rs.1.50  (Rupee one and paise fifty) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2021-22. The Company has fixed November 18, 2021 as the Record Date for the purpose of payment of Second Interim Dividend and the same will be paid on or before November 30, 2021.<BR> <BR> We also enclose a copy of the Press Release on Un-audited Financial Results of the Company for the Second Quarter and half year ended September 30, 2021.<BR> <BR>",
            "news_id": "1494f542-46f6-4379-8fd1-b840cad67041",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=61e29b8f-c5bf-4fb3-8624-0e92abe756dc.pdf",
            "news_date": "2021-11-08 19:27:08",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Please refer to our letter dated August 7, 2021 wherein we have intimated the schedule of Investors/ Analysts call on August 13, 2021. We are attaching herewith the Transcript of the analyst / investor call on the Un-audited Financial Results of the Company for the first quarter ended June 30, 2021 and the same is being uploaded on the website of the Company and is available in the following web link.<BR> <BR> https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/<BR>",
            "news_id": "bb086df3-fcd6-4967-85d7-a86c7c76beb9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=89e840e5-fd92-4d12-8935-2ea9f2967c17.pdf",
            "news_date": "2021-08-25 18:25:33",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please refer to our letter dated August 7, 2021 wherein we have intimated the schedule of Investors/ Analysts call on August 13, 2021.  In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the first quarter ended June 30, 2021.  The presentation is also being uploaded in the following web-link of the Company.",
            "news_id": "4927d679-33b1-4f8e-8221-1f34121e8040",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c466fb4d-b9a9-4731-8051-e46df3f4e152.pdf",
            "news_date": "2021-08-12 20:02:08",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Un-Audited Financial Results For First Quarter Ended June 30, 2021",
            "news_body": "The Board of Directors of the Company at its meeting held today, August 12, 2021, has inter alia, considered and approved the Un-audited Financial Results of the Company for the First Quarter ended June 30, 2021 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company.",
            "news_id": "76111d10-a19b-4f27-806d-ac23861f9e03",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=120bdacd-3987-4dee-b8ae-b5cfa1293e8d.pdf",
            "news_date": "2021-08-12 19:37:58",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
            "news_body": "The Board of Directors of the Company at its meeting held today, August 12, 2021, has inter alia, considered and approved:-<BR> <BR> 1.  the Un-audited Financial Results of the Company for the First Quarter ended June 30, 2021 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company.<BR> <BR> 2.  an Interim Dividend @ 150% i.e. Rs.1.50 (Rupee one and paise fifty) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2021-22. <BR> <BR>",
            "news_id": "42d43ea5-d7ea-44e2-abe7-6efb0e04d10f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ef5c7bdf-62e2-4834-9fc6-7d0683d6eb13.pdf",
            "news_date": "2021-08-12 18:57:27",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Please refer to our letter dated May 28, 2021 wherein we have intimated the schedule of Investors/ Analysts call on May 31, 2021. We are attaching herewith the Transcript of the analyst / investor call on the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2021 and the same is being uploaded on the website of the Company and is available in the following web link.<BR> <BR> https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/<BR>",
            "news_id": "d1c0b52e-58e7-4676-9af2-dbfcf46f9876",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=58f1f8e9-8272-46db-8bca-1f3c8434a55f.pdf",
            "news_date": "2021-06-11 11:45:08",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please refer to our letter dated May 28, 2021 wherein we have intimated the schedule of Investors/ Analysts call on May 31, 2021.  In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2021.  The presentation is also being uploaded in the following weblink of the Company.<BR> <BR> <BR>",
            "news_id": "3c4469e6-6f4e-43ca-8807-61dc85db434f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=31e9debd-32d4-4350-a71e-3b0e06cfd30b.pdf",
            "news_date": "2021-05-31 15:37:09",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For The Fourth Quarter And Year Ended March 31, 2021",
            "news_body": "The Board of Directors of the Company at its meeting held today, May 31, 2021, has inter alia, considered and approved the standalone and consolidated Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2021 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Audited Financial Results of the Company along with the Auditors Report issued by the Statutory Auditors. Pursuant to Regulation 33(3)(d) of SEBI Listing Regulations, we hereby confirm and declare that the Statutory Auditors of the Company, M/s. B S R & Associates LLP, Chartered Accountants, have issued the audit report on Standalone and Consolidated Financial Results of the Company for the fourth quarter and year ended March 31, 2021 with unmodified opinion.<BR> We also enclose a copy of the Press Release on Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2021.<BR>",
            "news_id": "b978da9a-a5e2-4305-99c2-4c3c8f00d461",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6041cff3-6bc0-4758-92c1-e7528c3b98eb.pdf",
            "news_date": "2021-05-31 13:32:29",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting",
            "news_body": "The Board of Directors of the Company at its meeting held today, May 31, 2021, has inter alia, considered and approved Audited Financial Results for the fourth quarter and year ended 31.03.2021 and other matters.",
            "news_id": "b56eb418-3d65-4f81-a187-570a81474ac2",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cc02b5d5-f0b1-4299-a022-16f0d3198062.pdf",
            "news_date": "2021-05-31 13:10:59",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Please refer to our letter dated February 9, 2021 wherein we have intimated the schedule of Investors/ Analysts call on February 11, 2021. We are attaching herewith the Transcript of the analyst / investor call on the Un-audited Financial Results of the Company for the third quarter and nine months period ended December 31, 2020 and the same is being uploaded on the website of the Company and is available in the following web link.<BR> <BR> https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/<BR>",
            "news_id": "b3551889-5ffb-44ce-90e8-899ddf06408e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=98656a6d-19d8-42c5-befc-955dbbb4254a.pdf",
            "news_date": "2021-02-25 10:29:59",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        }
    ]
}